Drug details

Monjuvi (tafasitamab-cxix injection)

type of Antineoplastics, Anti-CD19 Monoclonal Antibodies

Monjuvi (tafasitamab-cxix) is a CD19-directed cytolytic antibody indicated in combination with lenalidomide to treat adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT).

This drug may have the following side effects:

• nausea,
• vomiting,
• diarrhea,
• fever,
• shortness of breath,
• constipation,
• fatigue,
• cough,
• low blood potassium (hypokalemia),
• swelling of extremities,
• back pain, and
• decreased appetite,
• muscle spasms
• anemia,
• bronchitis,
• respiratory tract infection,
• low white blood cells (neutropenia),
• low blood platelets (thrombocytopenia),

The following drugs are related to Monjuvi, either as a replacement or used together:

• Trisenox (arsenic trioxide injection)
• Elspar (asparaginase)
• Theracys (bcg live (intravesical))
• Belrapzo (bendamustine hydrochloride injection)
• Breyanzi (lisocabtagene maraleucel suspension for intravenous infusion)
• Cerubidine (daunorubicin)
• Zinecard (dexrazoxane)
• Epkinly (epcoritamab-bysp injection)
• Toposar (etoposide injection)
• Nivestym (filgrastim-aafi injection)
• Idamycin (idarubicin)
• Idamycin PFS (idarubicin hydrochloride injection)
• Kymriah (tisagenlecleucel suspension for intravenous infusion)
• Lumoxiti (moxetumomab pasudotox-tdfk for injection)
• Oncaspar (pegaspargase)
• Truxima (rituximab-abbs injection)
• Ukoniq (umbralisib tablets)